Wave Life Sciences Ltd. (WVE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Verve Therapeutics, Inc.

Adaptive Biotechnologies Corp.

Kymera Therapeutics, Inc.

Wave Life Sciences Ltd.

Kura Oncology, Inc.

Inhibrx, Inc.

Curis, Inc.

Novavax, Inc.

Apogee Therapeutics, Inc.

Sana Biotechnology, Inc.

Cassava Sciences, Inc.

Why is Wave Life Sciences Ltd. ?

Flat results in Mar 26

NET SALES(HY) At USD 55.49 MM has Grown at -40.28%
NET PROFIT(HY) At USD -79.27 MM has Grown at -349.74%
OPERATING CASH FLOW(Y) Lowest at USD -185.51 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -6.09%, its profits have fallen by -110.7%

Below par performance in long term as well as near term

Along with generating -6.09% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Wave Life Sciences Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Wave Life Sciences Ltd.

-6.09%

0.03

170.55%

S&P 500

25.22%

1.91

13.23%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.30%

EBIT Growth (5y)

-10.82%

EBIT to Interest (avg)

-120.80

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.31

Sales to Capital Employed (avg)

1.40

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.28

EV to EBIT

-2.81

EV to EBITDA

-2.93

EV to Capital Employed

-8.96

EV to Sales

14.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-38.84%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

ROCE(HY)

Highest at -53.11%

RAW MATERIAL COST(Y)

Fallen by -23.29% (YoY

CASH AND EQV(HY)

Highest at USD 1,146.66 MM

NET SALES(Q)

Highest at USD 38.25 MM

OPERATING PROFIT(Q)

Highest at USD -28.99 MM

OPERATING PROFIT MARGIN(Q)

Highest at -75.81 %

PRE-TAX PROFIT(Q)

Highest at USD -26.09 MM

NET PROFIT(Q)

Highest at USD -26.09 MM

EPS(Q)

Highest at USD -0.13

-19What is not working for the Company

NET SALES(HY)

At USD 55.49 MM has Grown at -40.28%

NET PROFIT(HY)

At USD -79.27 MM has Grown at -349.74%

OPERATING CASH FLOW(Y)

Lowest at USD -185.51 MM

DEBT-EQUITY RATIO (HY)

Highest at -103.35 %

Here's what is working for Wave Life Sciences Ltd.

Net Sales

At USD 38.25 MM has Grown at 316.85%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Net Sales

Highest at USD 38.25 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -28.99 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -75.81 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -26.09 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -26.09 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.13

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 1,146.66 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -23.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 2.31 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Wave Life Sciences Ltd.

Operating Cash Flow

Lowest at USD -185.51 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Highest at -103.35 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio